Author

Moazah Iftikhar

Observed institution: Mayo Clinic

OpenAlex ID: A5111084402

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients

2023 · Naseema Gangat, Omer Karrar, et al. · American Journal of Hematology · 80

PDF

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

2023 · Omer Karrar, Maymona Abdelmagid, et al. · American Journal of Hematology · 50

PDF

Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents

2024 · Isla M. Johnson, Omer Karrar, et al. · British Journal of Haematology · 10

The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic Correlates

2025 · Masooma S. Rana, Moazah Iftikhar, et al. · American Journal of Hematology · 5

PDF

Cytogenetic abnormalities in polycythemia vera: phenotypic correlates and prognostic relevance in 669 informative cases

2025 · Moazah Iftikhar, Masooma Rana, et al. · Haematologica · 3

Revised International Working Group Risk Model for Survival in Polycythemia Vera

2024 · Ayalew Tefferi, Giuseppe Gaetano Gaetano Loscocco, et al. · Blood · 3

Sodium-Glucose Co-Transporter-2 Inhibitor Use in the Setting of Myeloproliferative Neoplasms: Impact on Hemoglobin/Hematocrit Levels and Thrombosis Risk

2023 · Naseema Gangat, Omer Karrar, et al. · Blood · 3

Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities

2026 · Giuseppe G. Loscocco, Fnu Aperna, et al. · American Journal of Hematology · 2

Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases

2024 · Moazah Iftikhar, Masooma S Rana, et al. · Blood · 2

PDF

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

2023 · Omer Karrar, Moazah Iftikhar, et al. · Blood · 2

Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia

2026 · Giuseppe G. Loscocco, Fnu Aperna, et al. · Blood Cancer Journal · 1

PDF

Cancers in Polycythemia Vera and Essential Thrombocythemia: A before and after Diagnosis Survey and Analysis of Risk Factors

2024 · Giuseppe Gaetano Loscocco, Fnu Aperna, et al. · Blood · 1

PDF

Autoimmune or Inflammatory Diseases in 1,968 Consecutive Patients with Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcome and Co-Morbidities

2024 · Fnu Aperna, Moazah Iftikhar, et al. · Blood · 1

PDF

Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients

2024 · Naseema Gangat, Giuseppe Gaetano Loscocco, et al. · Blood · 1

PDF

Basophilia in Polycythemia Vera Is Associated with an Increased Risk of Leukemic and Myelofibrotic Transformation

2024 · Mahlet Siraga, Maymona Abdelmagid, et al. · Blood · 1

Polycythemia Vera Vs. JAK2 Mutated or Wild-Type Essential Thrombocythemia: Clinical and Molecular Comparisons and Long-Term Outcome Among 2,010 Patients

2024 · Giuseppe Gaetano Loscocco, Moazah Iftikhar, et al. · Blood

The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates

2024 · Masooma S Rana, Moazah Iftikhar, et al. · Blood

PDF

ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival

2023 · Kristen McCullough, Omer Karrar, et al. · Blood

Works count: 18

Citation count: 165

H-index: 4

I10-index: 3